| Quantity: | |
|---|---|
Clinically relevant – Recapitulates human PsA with concurrent skin and joint inflammation, TNF-α/IL-17 axis involvement.
Multiple strains – DBA/1 (high susceptibility) and C57BL/6 (moderate, suitable for transgenic studies) available.
Comprehensive endpoints – Body weight, psoriasis score, arthritis score, skin and joint histopathology (HE), splenomegaly, cytokine profiling.
Translational value – Ideal for testing biologics (anti-TNF, anti-IL-17, anti-IL-23), JAK inhibitors, and immunomodulators.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
Mannan Induced PsA Model in DBA/1
Mannan Induced PsA Model in C57BL/6
• Efficacy testing of biologics targeting TNF-α (etanercept, adalimumab), IL-17 (secukinumab, ixekizumab), and IL-23 (guselkumab)
• Evaluation of JAK inhibitors (tofacitinib, upadacitinib), PDE4 inhibitors (apremilast), and small molecule immunomodulators
• Target validation for Th17/IL-17 axis and macrophage-T cell interactions in PsA
• Biomarker discovery (cytokine profiles, immune cell subsets)
• IND-enabling pharmacology and toxicology studies
Parameter | DBA/1 PsA Model | C57BL/6 PsA Model |
Species/Strain | DBA/1 mouse | C57BL/6 mouse |
Induction method | Intraperitoneal injection of mannan (10–20 mg/mouse) on day 0 and day 7 | |
Study duration | 7–21 days | 7–21 days |
Key endpoints | Body weight, psoriasis score (0–4), arthritis score (0–4), skin/joint histopathology (HE), splenomegaly, serum cytokines (TNF-α, IL-17A) | Body weight, psoriasis score (0–4), arthritis score (0–4), skin/joint histopathology (HE), splenomegaly, optional flow cytometry |
| Positive control | Anti-TNF antibody or dexamethasone | Anti-TNF antibody or dexamethasone |
Data package | Raw data, analysis reports, clinical scores, histology slides | Raw data, analysis reports, clinical scores, histology slides |
Q: What are the differences between DBA/1 and C57BL/6 PsA models?
A: DBA/1 mice are highly susceptible and develop robust skin and joint inflammation, making them ideal for efficacy studies. C57BL/6 mice develop a milder but reproducible phenotype and are suitable for genetic manipulation and transgenic studies.
Q: How is mannan-induced PsA different from other PsA models?
A: The mannan model uniquely combines both skin psoriasis-like lesions and joint inflammation within a single, rapid induction protocol. It is driven by TNF-α and IL-17A, mimicking human PsA pathogenesis, and is highly reproducible.
Q: Can these models be used for IND-enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different mannan doses, treatment timing)?
A: Absolutely. Our scientific team tailors induction protocols, treatment schedules, and endpoint analyses to your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: Studies typically run 14–21 days post-induction, with disease onset within 3–5 days and peak scores around day 10–14.
